Cory Freedland
Director/Board Member presso Palvella Therapeutics, Inc.
Profilo
Cory S.
Freedland is a Director in multiple companies including Omniox, Inc., Palvella Therapeutics, Inc., Neurogene, Inc., Nura Bio, Inc., Tentarix Biotherapeutics LP, Tentarix Biotherapeutics, Inc., Nalo Therapeutics, Inc., Covid Apollo Project LLC, and Orsobio, Inc. She is also an Independent Director at Neurogene, Inc. starting in 2023 and a Partner at Samsara Biocapital LLC since 2017.
Previously, she held Director positions at Rainier Therapeutics, Inc. and Velicept Therapeutics, Inc. She was also a Principal at Sofinnova Investments, Inc. from 2014 to 2017 and a Vice President at Morgan Stanley from 2010 to 2013.
She has also worked as an Analyst at Morgan Stanley & Co. LLC and an Associate at Merrill Lynch, Pierce, Fenner & Smith, Inc. She holds a doctorate degree from Wake Forest University, an undergraduate degree from Connecticut College, and an MBA from Kellogg School of Management.
Posizioni attive di Cory Freedland
| Società | Posizione | Inizio |
|---|---|---|
Palvella Therapeutics, Inc.
 Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Director/Board Member | - |
Nura Bio, Inc.
 Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Director/Board Member | - |
Neurogene, Inc.
 Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Director/Board Member | - |
Nalo Therapeutics, Inc.
 Nalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nalo Therapeutics, Inc. is a company that focuses on developing therapeutics to address unmet needs in cancer. Nalo Therapeutics is based in Belmont, CA and the CEO of the company is Keith Wilson. The company targets oncogenic driver mutations and/or proteins that are often difficult to drug. The company was founded in 2017 and collaborates with UCSF scientific cofounders. | Director/Board Member | - |
| Tentarix Biotherapeutics, Inc. | Director/Board Member | - |
Omniox, Inc.
 Omniox, Inc. Pharmaceuticals: MajorHealth Technology Omniox, Inc. operates as a biopharmaceutical company which develops medicines for hypoxic diseases. Its technology overcomes fundamental biochemical shortcomings of hemoglobin-based and per fluorocarbon oxygen delivery approaches. The company was founded in 2006 by Stephen P. L. Cary, Michael A. Marletta, Jonathan Winger and Elizabeth Marshall Boon and is headquartered in San Carlos, CA. | Director/Board Member | - |
Tentarix Biotherapeutics LP
 Tentarix Biotherapeutics LP BiotechnologyHealth Technology Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA. | Director/Board Member | - |
Covid Apollo Project LLC
 Covid Apollo Project LLC Financial ConglomeratesFinance Covid Apollo Project LLC aims to facilitate a safe and sustainable return to work and school by identifying, assembling, developing, and scaling the most promising COVID-19 diagnostic opportunities. Covid Apollo Project is based in Boston, MA. The private company was organized and funded under the leadership of RA Capital, a biotechnology-focused investment firm, in collaboration with Redmile Group, Samsara Biocapital, Perceptive Advisors, and Bain Capital. The CEO of the company is Stefan Willemsen. | Director/Board Member | - |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01/10/2017 |
| ░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Precedenti posizioni note di Cory Freedland
| Società | Posizione | Fine |
|---|---|---|
| ░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░░░░ ░░░░░░ ░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Cory Freedland
| Wake Forest University | Doctorate Degree |
| Connecticut College | Undergraduate Degree |
| Kellogg School of Management | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MORGAN STANLEY | Finance |
| Aziende private | 17 |
|---|---|
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Finance |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Finance |
Omniox, Inc.
Omniox, Inc. Pharmaceuticals: MajorHealth Technology Omniox, Inc. operates as a biopharmaceutical company which develops medicines for hypoxic diseases. Its technology overcomes fundamental biochemical shortcomings of hemoglobin-based and per fluorocarbon oxygen delivery approaches. The company was founded in 2006 by Stephen P. L. Cary, Michael A. Marletta, Jonathan Winger and Elizabeth Marshall Boon and is headquartered in San Carlos, CA. | Health Technology |
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Finance |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
Velicept Therapeutics, Inc.
 Velicept Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Velicept Therapeutics, Inc. manufactures biopharmaceutical products. The firm offers Solabegron, which is used for the treatment of overactive bladder in women and irritable bowel syndrome. The company was founded in 2015 and is headquartered in Wayne, PA. | Health Technology |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. BiotechnologyHealth Technology Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA. | Health Technology |
Neurogene, Inc.
Neurogene, Inc. BiotechnologyHealth Technology Neurogene, Inc. focuses on developing disease modifying therapeutics for severe neurologic diseases. Its pipeline includes multiple gene therapy products for ultra-rare diseases, as well as a novel technology that has the potential for use in monogenic autism spectrum disorders and indications not well suited for gene therapy. The company was founded by Rachel McMinn in January 2018 and is headquartered in New York, NY. | Health Technology |
Nura Bio, Inc.
Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
Tentarix Biotherapeutics LP
Tentarix Biotherapeutics LP BiotechnologyHealth Technology Tentarix Biotherapeutics LP operates as a biotechnology company. The company is headquartered in La Jolla, CA. | Health Technology |
Jiya Acquisition Corp.
 Jiya Acquisition Corp. Financial ConglomeratesFinance Jiya Acquisition Corp. is a blank check company. The firm was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on identifying promising opportunities in the biopharmaceutical sector. The company was founded in August 2020 and is headquartered in Palo Alto, CA. | Finance |
| Tentarix Biotherapeutics, Inc. | |
Nalo Therapeutics, Inc.
Nalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nalo Therapeutics, Inc. is a company that focuses on developing therapeutics to address unmet needs in cancer. Nalo Therapeutics is based in Belmont, CA and the CEO of the company is Keith Wilson. The company targets oncogenic driver mutations and/or proteins that are often difficult to drug. The company was founded in 2017 and collaborates with UCSF scientific cofounders. | Health Technology |
Covid Apollo Project LLC
Covid Apollo Project LLC Financial ConglomeratesFinance Covid Apollo Project LLC aims to facilitate a safe and sustainable return to work and school by identifying, assembling, developing, and scaling the most promising COVID-19 diagnostic opportunities. Covid Apollo Project is based in Boston, MA. The private company was organized and funded under the leadership of RA Capital, a biotechnology-focused investment firm, in collaboration with Redmile Group, Samsara Biocapital, Perceptive Advisors, and Bain Capital. The CEO of the company is Stefan Willemsen. | Finance |
OrsoBio Inc
 OrsoBio Inc Miscellaneous Commercial ServicesCommercial Services Orsobio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing therapies to treat obesity and other severe metabolic disorders, such as type 2 diabetes, NASH, and severe dyslipidemias. The company is based in Palo Alto, CA. The company has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. Orsobio has a team of physicians and scientists who are dedicated to developing therapies to treat organ failure in patients with severe metabolic disorders. The company was founded by Mani Subramanian, who has been the CEO since incorporation. | Commercial Services |
Merrill Lynch, Pierce, Fenner & Smith, Inc.
 Merrill Lynch, Pierce, Fenner & Smith, Inc. Investment Banks/BrokersFinance Founded in 1958, Merrill Lynch Piece Fenner & Smith, Inc. is an SEC registered broker/dealer located in New York City. The firm is a subsidiary of BAC North America Holding Co. and their ultimate parent is Bank of America Corp. (NYSE BAC). | Finance |
- Borsa valori
- Insiders
- Cory Freedland
